Near doubling of survival at 1 and 2 years in pretreated patients1

2nd line treatment
Read more about second-line treatment

A consistent efficacy in first-line patients1

1st line treatment
Read more about first-line treatment

Novel Mechanism of Action

In contrast to cytotoxic chemotherapy drugs, YERVOY™ works by activating the patient’s own immune system to destroy melanoma tumours. (1,4)
More information


Specific patterns of response

As it can take some time to prime the immunesystem to fight the tumour, it is not surprising that many advanced (unresectable or metastatic) melanoma patients display atypical, delayed responses to YERVOY™. (4)
More information


1. YERVOY™ Summary of Product Characteristics.
2. Eggermont AM. Advances in systemic treatment of melanoma. Ann Oncol. 2010;21 Suppl 7:vii339-vii344.
3. European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) Assessment Report For YERVOY® (ipilimumab) 24 October 2013.
4. Hoos A et al. J Natl Cancer Inst. 2010 Sep 22;102(18):1388-1397.

Senast uppdaterad:  2015-07-02Ansvarig:  Anna Labecker